The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2017 | Prospects of treating CLL and their complications
Nitin Jain, MD, from the University of Texas MD Anderson Cancer Center, Houston, TX, gives us an overview on the three abstracts detailed in his talk on treating chronic lymphocytic leukemia (CLL), presented at the American Society of Oncology (ASCO) 2017 Annual Meeting in Chicago, IL. The positive results obtained from a trial involving lenalidomide maintenance for CLL patients who have received a fludarabine and rituximab regimen (NCT00860457) are described here. He also talks about a Phase III trial involving the administration of ublituximab in combination with ibrutinib in treating CLL (NCT02301156), as well as a retrospective analysis on Richter’s Transformation, an unwanted complication observed in many CLL patients.
